Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
Amandine GouverneurPaola Sanchez-PenaGwenaelle VeyracJoe-Elie SalemBernard BégaudJulien BezinPublished in: Cardiovascular drugs and therapy (2021)
This study identified a signal of neurocognitive disorders associated with PCSK9 inhibitors and encourages paying attention to at-risk populations.